Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-02-06
2000-09-19
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424409, 424452, 424455, 424465, 514946, A61K 3112
Patent
active
061212342
ABSTRACT:
A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally coadministering the pharmaceutical compound to a mammal in need of treatment with the compound with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0.01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine, and 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4.
REFERENCES:
patent: 4822816 (1989-04-01), Markham
patent: 4849227 (1989-07-01), Cho
patent: 4944949 (1990-07-01), Story et al.
patent: 4968716 (1990-11-01), Markham
patent: 5070085 (1991-12-01), Markham
patent: 5156842 (1992-10-01), Mulligan
patent: 5179122 (1993-01-01), Greene et al.
patent: 5284657 (1994-02-01), Lu et al.
patent: 5332747 (1994-07-01), Van Dyke
patent: 5350756 (1994-09-01), Smith
patent: 5409690 (1995-04-01), Howell et al.
patent: 5422350 (1995-06-01), Woolf
patent: 5424289 (1995-06-01), Yang et al.
patent: 5436243 (1995-07-01), Sachs et al.
patent: 5455286 (1995-10-01), Amidon et al.
patent: 5466696 (1995-11-01), Woolf
patent: 5487898 (1996-01-01), Lu et al.
Adams, M.W., d-Alpha Tocopheryl Polyethylene glycol 1000 Succinate (Eastman vitamin E TPGS) as an Emulsifier and Bioenhancer for Drugs and Lipophilic Compounds, 6th International Conference on Pharmaceutical technology, Paris, June 2-4, 1992.
Albengres et al., "Cyclosporin and Ketoconazole, Drug Interaction or Therapeutic Association?", International Journal of Clinical Pharmacology et al., 39(12): 555-570, 1992.
Arias, I.M. et al., "Structure & Function of P-Glycoprotein in the Normal Liver", Xenobiotics and Cancer (L. Ernster et al., eds.), Japan Sci. Soc. Press, Tokyo/Taylor & Francis, Ltd., London, pp. 229-239, 1991.
Akitoshi et al., Abstract "Acceleration of Transdermal Absorption of Pharmaceuticals by Essential Oils and Organic Solvents", Chem Abst., 112:125228t, 1990.
Baciewicz et al., "Ketoconazole and Fluconazole Drug Interactions", Archives of Internal Medicine, 153(17):1970-76, 1993.
Back et al., "Comparative Effects of two Antimycotic Agents, Ketoconazole and Terbinafine on the Metabolism of Tolbutamide, Ethinyloestradiol, Cyclosporin and Ethoxycoumarin by Human Liver Microsomes In Vitro", British Journal of Clinical Pharmacology, 28:166-170, 1989.
Back et al., "Azoles, Allylamines and Drug Metabolism", British Journal of Dermatology, Supplement 39, 126:14-18, 1992.
Back, David J., and Orme, Michael L'E.; "Pharmacokinetic Drug Interactions with Oral Contraceptives", (1990) Clin. Pharmacokinet. 18(6):472-484.
Bonkovsky et al., "Cytochrome P.sub.450 of Small Intestinal Epithelial Cells," Gastroenterology, 88:458-467 (1985).
Bradford, "A Rapid and Sensitive Method for the Quantification of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," Analytical Biochemistry, 72:248-254 (1976).
Callaghan, Richard and Riordan, John R.; "Synthetic and Natural Opiates Interact with P-glycoprotein in Multidrug-resistant Cells", (1993) J. Biol. Chem. 268(21):16059-16064.
Chan et al., "Drug Interactions with Cyclosporine: Focus on Antimicrobial Agents", Clinical Transplantation, 6:(3)(1):141-153, Jun. 1992.
Chang, Tammy et al., "The Effect of Water-Soluble Vitamin E on Cyclosporine Pharmacokinetics in healthy Volunteers", Abstract in American Society to Clinical Pharmacology and Therapeutics, 57(2):163, Feb. 1995.
Clynes, Martin; "Cellular Models for Multiple Drug Resistance in Cancer", (1993) In Vitro Cell. Dev. Biol. 29A:171-179.
de Smet et al., "Combined use of Cyclosporine and Ketocanazole in the treatment of Endogenous Uveitis", American Journal of Ophthalmology, 113:687-690, Jun. 1992.
Endicott, Jane A., and Ling, Victor; "the Biochemistry of P-glycoprotein-mediated Multidrug Resistance", (1989) Annu. Rev. Biochem., 58:137-171.
Fahr, Alfred; "Cyclosporin Clinical Pharmacokinetics" (1993) Clin. Pharmakokinetic, 24(6):472-495.
Fairchild, Craig R., and Cowan, Kenneth H.; "Keynote Address: Multidrug Resistance: A Pleiotropic Response To Cytotoxic Drugs" (1991) Int. J. Radiation Oncology Biol. Phys., 20:361-367.
Fasco, Michael J. et al.; "Rat Small Intestinal Cytochromes P450 Probed by Warfarin Metabolism" (1993) Mol. Pharmacol., 43:226-233.
First et al., "Concomitant Administration of Cyclosporin and Ketoconazole in Renal Transplant Recipients", The Lancet, 2:1198-1201, Nov. 18, 1989.
First et al., "Cyclosporine Dose Reduction by Ketoconazole Administration in Renal Transplant Recipients", Transplantation, 52(2):365-370, Feb. 1991.
Fojo, Antonio T.; "Multidrug Resistance" (1991) Adv. Intern. Med., 36:195-218.
Gatmaitan, Zenaida C. and Irwin M. Arias; "Structure and Function of P-Glycoprotein in Normal Liver and Small Intestine" (1993) Adv. Pharmacol., 24:77-97.
Greenblatt, David J.; "Presystemic Extraction: Mechanisms and Consequences" (1993) J. Clin. Pharmacol, 33:650-656.
Hait et al., "Terfenadine (Seldane.COPYRGT.): New Drug for Restoring Sensitivity to Multidrug Resistant Cancer Cells," Bioch. Pharm., 45(2):401-406 (1993).
Hebert, Mary F. et al.; "Bioavailability of Cyclosporine with Concomitant Rifampin Administration is Markedly Less Than Predicted by Hepatic Enzyme Induction" (1992) Clin. Pharmacol. Ther., 52:453-457.
Henricsson et al., "Cyclosporin Metabolism in Human Liver Microsomes and its Inhibition by Other Drugs", Pharmacology & Toxicology, 66:49-52, 1990.
Hsing et al., "The Function of Gp170, the Multidrug-Resistance Gene Product, in the Brush Border of Rat Intestinal Mucosa," Gastroenterology, 102:879-885 (1992).
Hunter, J. et al., "Epithelial Secretion of Vinblastine by Human Intestinal Adenocarcinoma Cell (HCT-8 and T84) Layers Expressing P-Glycoprotein", British Journal of Cancer, 64:437-444, 1991.
Hunter, Janice et al.; "Functional Expression of P-glycoprotein in Apical Membranes of Human Intestinal Caco-2 Cells" (1993) J. Biol. Chem., 268:14991-14997.
Jancis, Erik M. et al.; "Estradiol Induction of Rhodamine 123 Efflux and the Multidrug Resistance Pump in Rat Pituitary Tumor Cells" (1993) Mol. Pharmacol., 43:51-56.
Kaminsky, Laurence, and Michael J. Fasco; "Small Intestinal Cytochromes P450" (1992) Toxicology, 21(6):407-422.
Kolars, Joseph C. et al.; "Identification of Rifampin-inducible P450IIIA4 (CYP3A4) in Human Small Bowel Enterocytes" (1992) J. Clin. Invest., 90:1871-1878.
Kolars, Joseph C. et al.; "Heterogeneity of Cytochrome P450IIIA Expression in Rat Gut Epithelia" (1992) Gastroenterology, 102:1186-1198.
Kolars, Joseph C. et al.; "Cyclosporine Metabolism by P450IIIA in Rat Enterocytes--Another Determinant of Oral Bioavailability?" (1992) Transplantation, 53:596-602.
Komori, Masayuki et al.; "Cyrochrome P-450 in Human Liver Microsomes: High-Performance Liquid Chromatographic Isolation of Three Forms and Their Characterization" (1988) J. Biochem., 104:912-916.
Kralovanszky, et al.; "Isolation of Viable Intestinal Epithelial Cells and Their Use for in Vitro Toxicity Studies", In Vivo, 4:201-204, 1990.
Kronbach, Thomas et al.; "Oxidation of Midazolam and Triazolam by Human Liver Cytochrome P450IIIA4" (1989) Molec. Pharm., 36:89-96.
Kronbach et al., "Cyclosporine Metabolism in Human Liver: Identification of a Cytochrome P-450III Gene Family as the Major Cyclosporine-Metabolizing Enzume Explains Interactions of Cyslosporine with Other Drugs," Clin. Pharmacol. Ther., 43(6):630-635 (1988).
Lalka et al.; "The Hepatic First-Pass Metabolism of Problematic Drugs" (1993) J. Clin. Pharmacol., 33:657-669.
Ludescher et al.; "Rapid Functional Assay for the Detection of Multidrug-Resistant Cells Using the
Benet Leslie Z.
Benet Reed M.
Wacher Vincent J.
AvMax, Inc.
Reamer James H.
LandOfFree
Use of essential oils to increase bioavailability of orally admi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of essential oils to increase bioavailability of orally admi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of essential oils to increase bioavailability of orally admi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073263